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Injection of sterile aqueous preparations of the peptidoglycan polysaccharide of group A streptococci
produces chronic inflammation in several animal models. Accordingly, the effect of peptidoglycan and group A-
specific polysaccharide (PG-APS) polymers on human polymorphonuclear neutrophil oxidative metabolism
was studied with the supposition that this interaction may contribute to the inflammation observed. PG-APS in
concentrations of 1.0 to 100 ,ug/ml stimulated oxygen consumption and hexose monophosphate shunt activity in
the presence of 10% normal serum in a dose-related manner. Stimulation did not occur in serum-free media
and was reduced in media with heat-treated serum. The stimulation of hexose monophosphate shunt activity by
PG-APS opsonized with normal serum (bound complement components) and the activated supernatant from
which PG-APS had been removed by centrifugation (presumably containing the soluble complement
component, C5a) demonstrated 79 and 75%, respectively, of the stimulation with PG-APS in the presence of
10% normal serum. PG-APS triggered release of O2- (3.4 ± 2.0 nmol by 106 human polymorphonuclear
neutrophils over 30 min), which was significantly enhanced (9.6 ± 2.9 nmol O2-) by treatment of cells with
cytochalasin B. These results show that PG-APS interacts with serum in such a fashion as to activate human
polymorphonuclear neutrophil metabolism and increase secretion of O2-
Purified group A streptococcal cell walls consist of cova-
lently bound polymers of peptidoglycan and group A-specif-
ic polysaccharide (PG-APS) (21). The group-specific carbo-
hydrate moiety consists of a backbone of rhamnose with
repeating epitopes of N-acetylglucosamine. The peptidogly-
can moiety is made up of repeating units of the disaccharide,
N-acetylglucosamine-N-acetylmuramic acid with peptide
side chains bound to the muramic acid through a lactyl group
on C3.
Injection of animals with sterile aqueous preparations of
PG-APS produced several models of chronic inflammation.
The localization of tissue injury produced by PG-APS de-
pends on the site of injection and the species or strain of
animal: a single intradermal injection of rabbits induced
recurrent multinodular lesions of the skin (32); intravenous
or intraperitonial injection of mice resulted in a pancarditis
(8); injection into rat gingival tissues produced periodontitis
(16); and systemic injection of rats produced a remittant
polyarthritis (7, 9).
The prolonged inflammation observed in these experimen-
tal models may result from the ability of the group A
polysaccharide to protect the biologically active peptidogly-
can from degradation (1, 30, 33). The peptidoglycan moiety is
responsible for inducing an inflammatory reaction character-
ized by vascular damage and extensive infiltration with
lymphocytes, polymorphonuclear neutrophils (PMNs), and
macrophages (7, 10, 25). The precise mechanism by which
PG-APS initiates and maintains tissue injury is not known.
However, a potential mechanism of tissue injury could be
provided by phagocytic cells activated by ingestion of bacte-
rial debris. The cell wall fragments persist within cultured
macrophages for up to 40 days (34) and appear to be
minimally degraded by PMNs (2, 3, 10, 13).
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The potential ramifications of the interaction of PG-APS
with phagocytic cells have been studied only to a limited
extent. Smialowicz and Schwab demonstrated a defect in
phagocytosis in rat macrophages (36) and rabbit PMNs
incubated with PG-APS (18) and in the activation of rat
macrophages to become cytotoxic (35). More recently, Pryz-
wansky et al. (26) have shown that binding of PG-APS
opsonized with the soluble complement component C3b
leads to capping of human PMNs. In the present study, we
further define the consequences of interaction of PG-APS
with human PMNs. Our results emphasize the possibility
that phagocytic cells are involved in the inflammation and
tissue damage associated with accumulation of PG-APS.
MATERIALS AND METHODS
Reagents. Ferricytochrome c (horse heart cytochrome c
type VI) obtained from Sigma Chemical Co. (St. Louis, Mo.)
was prepared in bicarbonate-buffered (pH 7.4) Hanks bal-
anced salt solution (HBSS) at a concentration of 0.8 mM
before use each day.
[1-14C]glucose was obtained from New England Nuclear
Corp. (Boston, Mass.). Zymosan (Sigma) was prepared in
HBSS each day. Dimethyl sulfoxide was obtained from
Sigma. Cytochalasin B was purchased from Sigma, dis-
solved in dimethyl sulfoxide to a concentration of 1 mg/ml,
and frozen at -20°C. Fresh samples were thawed before use
each day. Previous work has shown that neither cytochala-
sin B or dimethyl sulfoxide in the concentrations used
interfered with assays or cell survival (28).
Bacterial cell wall preparation. The details of the bacterial
cell wall preparation have been described (12). Briefly,
group A, type 3, strain D-58 streptococci were grown in
Todd-Hewitt broth (BBL Microbiology Systems, Cockeys-
ville, Md.) at 37°C to early stationary phase in a VirTis
fermentor (The VirTis Co., Inc., Gardiner, N.Y.). The cells
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were collected and washed in a Pellicon filtration unit
(Millipore Corp., Bedford, Mass.) and disrupted in a Braun
shaker (Bronwill Scientific, Inc., Rochester, N.Y.). Cell
walls were collected by differential centrifugation; treated
with trypsin, ribonuclease, papain, and chloroform-metha-
nol; and washed five times. Cell wall fragments were pre-
pared by suspension in phosphate-buffered saline (pH 7.2)
and subjected to sonic treatment for 70 min in a Iranson
model 350 sonifier (Branson Sonic Power Co., Danbury,
Conn.). After sonication, the walls were passed through a
Millipore 0.45-,um filter, and the concentrations of rham-
nose, N-acetylglucosamine, and N-acetylmuramic acid were
measured by gas chromatography. This material is the PG-
APS used in this study. Sterility was confirmed by culture on
blood agar plates.
Separation of PG-APS fragments by differential centrifuga-
tion. To derive a more homogeneous preparation which
could be readily washed, PG-APS was centrifuged at 10,000
x g for 30 min in a Sorvall SS-34 rotor to remove the largest
particles. The supernatant was centrifuged at 100,000 x g for
60 min in a T-865 rotor in a Sorvall OTD-D ultracentrifuge.
The pellets from this centrifugation were resuspended in
phosphate-buffered saline (pH 7.2) with 30 s of sonication
and labeled the 100p60 fraction.
Neutrophil separation. Heparinized venous blood from
normal human donors was separated on Plasmagel (Roger
Bellon Laboratories, Neuilly, France), and a neutrophil rich
fraction was obtained by Ficoll-Hypaque gradient centrifu-
gation, followed by dextran sedimentation and hypotonic
lysis of the erythrocytes as previously described (29). The
final preparations contained 98% neutrophils, and 98% of the
neutrophils were viable as determined by trypan blue dye
exclusion. In all phagocytic and metabolic assays, except
where noted below, the final PMN concentration was 5.0 x
106 PMNs per ml, and the suspending medium was HBSS.
Preparation of serum, zymosan, and opsonization. Fresh
serum was obtained from the clotted blood of normal AB
donors and stored at -70°C. Opsonization of zymosan was
achieved by incubating the particles in 50% serum for 30 min
at 37°C. The opsonized particles were washed twice with
HBSS. In experiments with zymosan, final suspensions
contained ca. 100 particles per PMN.
Opsonization of bacterial cell wall fragments was achieved
by incubation in 50% serum for 30 min at 37°C. The
opsonized cell wall fragments were then washed twice by
resuspension and ultracentrifugation in HBSS. In some
experiments, the supernatant from the first wash was saved.
Heat-inactivated serum was prepared by being heated at
56°C for 30 min.
Measurement of oxygen consumption. Oxygen consump-
tion of cell suspensions containing 5 x 106 PMNs per ml in
HBSS was measured in the chamber of a Clark oxygen
electrode monitor (Yellow Springs Instrument Co., Yellow
Springs, Ohio) for 15 min at 37°C (29). Results are expressed
as the maximal rate of 02 consumption per minute.
Measurement of superoxide release. Superoxide (O2) was
measured by the superoxide dismutase-inhibitable reduction
of ferricytochrome c by the technique of Babior et al. (4)
with a minor modification. To duplicate the environment of
the oxygen consumption system in the Clark oxygen elec-
trode monitor, suspensions from the same donors containing
80 nmol of ferricytochrome c (and when appropriate 5 ,ug of
cytochalasin B per ml) were rotated continuously with
stimuli at 37°C in test tubes (12 by 15 mm). Controls
consisted of unstimulated cell preparations. Ferricyto-
chrome c reduction was measured in a rapid-scanning dual
spectrophotometer (model Acta C I1; Beckman Instru-
ments, Inc., Fullerton, Calif.).
Measurement of [1-_4C]glucose oxidation. The conversion
of [1-14C]glucose to 14Co2 by PMNs for 30 min at 37°C in a
rubber-stoppered glass flask was employed as a measure of
the oxidation of glucose via the hexose monophosphate
shunt (HMS) (29). 14Co2 was collected in alkali and mea-
sured in a liquid scintillation counter (29).
Statistics. The statistical analysis employed was the Stu-
dent's t test when more than three experiments were per-
formed. Probability values <0.05 for differences between
control and experimental preparations were considered to be
significant.
RESULTS
PG-APS stimulation of PMNs. A number of agents are
known to stimulate the metabolic activity of PMNs in a
manner similar to phagocytosis, possibly through their effect
on the plasma membrane (19). The products of the respira-
tory burst include superoxide anion, which if released extra-
cellularly could cause local tissue damage. In these experi-
ments, we investigated whether PG-APS initiated the
neutrophil respiratory burst. Suspensions containing 5 x 106
PMNs per ml were added to the oxygen electrode chamber
of a glass flask which contained concentrations of PG-APS
from 1.0 to 100 ,ug/ml and no serum. Oxygen consumption
and [1-'4C]glucose oxidation were measured. Under these
conditions, PG-APS did not stimulate neutrophil oxidative
metabolism (data not shown). However, in the presence of
10% normal serum, PG-APS stimulated a 225% increase in
HMS activity and a 266% increase in oxygen consumption
compared with resting (unstimulated) cell preparations. A
maximal response was observed at a concentration of 50 ,ug
of PG-APS per ml (Fig. 1 and 2). In each case, opsonized
zymosan was used as a positive control and for purposes of
comparison.
Relationship between 02 consumption and O2- release
among PG-APS-stimulated cells. Phagocytosis is associated
with consumption of 02, most of which is reduced to O2
and secreted into phagocytic vacuoles. However, some
stimuli (e.g., phorbol myristate acetate) lead to extracellular
release of virtually all the O2- formed, and phorbol myristate
acetate dramatically enhances lysis of extracellular targets
such as tumor cells (23). Because of these observations, we
determined the relationship between 02 consumed and O2
formed. PG-APS (50 jig/ml) was added to cell preparations in
10% serum. Oxygen consumption and superoxide generation
were measured concurrently over 30 min. Under these
conditions, 17.6 + 2.9 nmol of 02 was consumed, and 3.4 +
2.0 nmol of superoxide anion (20% of the 02 consumed) was
released per 106 cells (n = 4) (Fig. 3). Cytochalasin B
prevents phagosome closure and thereby enhances recovery
of O2 formed, which would normally be trapped in phago-
cytic vacuoles (19, 28). Cell preparations were preincubated
with 5 pug of cytochalasin B per ml for 5 min before use.
Under these conditions, 13.4 + 4.5 nmol of 02 was con-
sumed (n = 4), and 9.6 ± 2.9 nmol (72% of 02 consumed) of
O2 was recovered per 106 cells (Fig. 3). These results show
that binding of PG-APS is associated with the formation and
release of O2 and is similar to other opsonized particles in
its interaction with PMNs.
Effect of heat-inactivated serum and opsonized PG-APS on
PMN stimulation. The above experiments demonstrated that
PG-APS did not directly initiate the respiratory burst,
whereas a positive response was demonstrated in the pres-
ence of serum. To determine which components of serum
VOL. 45, 1984









the use of heat-inactivated serum (data not shown). These
results are consistent with earlier work which demonstrated
that PG-APS in the concentration employed in our studies
leads to complement activation (15). There are at least two
ways in which complement might lead to PG-APS-mediated
PMN stimulation. First, the soluble complement component
C5a is generated during complement activation and may bind
directly to the PMN membrane and stimulate oxidative
metabolism (14). Alternatively, PG-APS may be opsonized
by C3b and stimulate the PMN by binding to C3b receptors
(26); furthermore, both mechanisms may occur simultane-
ously. Accordingly, a preparation of 100p60 PG-APS parti-
cles (prepared by ultracentrifugation at 100,000 x g) was
preopsonized with 50% normal serum.
After incubation with serum, the PG-APS was centrifuged
at 100,000 x g, and the supernatant was then removed and
stored at -70°C. Both PG-APS preopsonized with normal
serum (pellet from 100,000 x g) as well as the supernatant
fluid (presumably containing soluble complement oompo-
FIG. 1. Comparison of the effect of 50 ,ug of PG-APS per ml with
10o normal serum and serum-free media on PMN 02 Qonslimption.
Each individual experiment was performed in duplicate. Bars repre-
sent the mean and brackets the standard deviation of the number of
separate experiments shown in parentheses. Opsonized zymosan
was used as a positive control.
were involved in PG-APS stimulation of oxidative metabo-
lism, heat-inactivated serum was employed. Release of 02
by PMNs stimulated by PG-APS was reduced 61% (P <
0.0025) when normal serum was replaced by serum heated at
56CC for 30 min to inactivate complement (Table 1). Trigger-



































FIG. 2. PG-APS stimulated PMN HMS activity in a dose-related
fashion when 10% normal serum was added to the media, Opsonized
zymosan was used as a positive control. Each individual experiment
was performed in triplicate. Bars represent the mean and brackets
the standard deviation of the number of separate experiments shown
in parentheses.
Resting PMNs 50,pg/mi PG-APS 50,og/ml PG-APS
+ cyto-B
FIG. 3. Relationship between 02 consumption and 02- release
among PG-APS-stimulated cells. Normal serum (10%) was present
in all systems. Each individual experiment was performed in dupli-
cate. Bars represent the mean and brackets the standard deviation of
thc number of separate experiments shown in parentheses. In one
preparation (far right), cells were preincubated with 5 ,ug of cytocha-
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TABLE 1. Effect of heat-inactivated serum on PG-APS
stimulation of 02- release'
System Mean (nmol) ± SDof 0.- released in 3 expt
Resting PMNs (10% normal serum) ....... 0.48 ± 0.39
PMNs + 50 1Lg of PG-APS per ml (10%
normal serum) ............. ........... 31.73 t 6.36
Resting PMNs (10% HI serum) ...... ..... 2.23 ± 0.49
PMNs + 50 ,ug of PG-APS per ml (10% HI
serum) ............................... 12.26b ± 5.68
a Cells were preincubated with 5 ,ug of cytochalasin B per ml before
challenge with 50 pLg of PG-APS per ml. All experiments were performed in
duplicate. HI, Heat inactivated.
b Significant difference (P < 0.0025) compared with systems with PMNs, 50
pLg of PG-APS per ml, and 10% normal serum. Heat-inactivated serum was
prepared as described in the text.
nents) stimulated HMS activity (Table 2). The stimulation by
preopsonized PG-APS and supernatant was 100 and 70%,
respectively, of the stimulation observed with PG-APS in the
presence of serum. The first wash material lost activity with
time when frozen at -70°C (data not shown).
DISCUSSION
A single injection of an aqueous suspension of group A
streptococcal cell wall (PG-APS) produces chronic, remit-
tant inflammation in the joints, heart, intestine, or skin; the
location of lesions depends on the animal species and
injection route (3i). In the early phase of the inflammatory
reaction and during exacerbations, PMNs are observed
within the lesion (10). However, no previous studies have
been performed to investigate the effects of PG-APS on
PMN function, although these cells could be involved in the
tissue injury associated with PG-APS administration.
Accordingly, we studied the effects of PG-APS on neutro-
phil oxidative metabolism. The PMN responds to perturba-
tions of the plasma membrane with a burst of oxygen
consumption, increased HMS activity, and formation of
microbicidal oxygen reduction products (20). Our results
show that PG-APS does, not stimulate PMN oxygen con-
sumption or oxidition of [1-14C]glucose in the absence of
Ferum. However, in the presence of 10% normal serum, a
concentration of PG-APS between 1.0 to 50.0 ,ug/ml leads to
significant stimulation of PMN 02 consumption and glucose
oxidation, with maximal effect of PG-APS at 50 ,ug/ml. PMN
activation by PG-APS was markedly reduced when heat-
inactivated serum was used, suggesting that complement or
other heat-labile factors are of greatest importance. Green-
blatt and co-workers reported activation of the alternate
complement pathway in human serumh by peptidoglycan and
cell wall preparations of group A streptococci (15). In
addition, with a flourescent antibody technique, Pryzwansky
et al. observed binding of PG-APS opsonized with normal
serum or C3b (26). Their study also showed that binding did
not occur in the absence of fresh serutm or when heqt-
inactivated serum was used (26). However, the residual
stimulation of O2 release by PG-APS in heat-inactivated
serum suggests that under these conditions, antibody may
directly mediate some binding or lead to an aggregation of
PG-APS sufficient to allow membrane perturbation or
phagocytosis.
These results suggested that complement actiVation by
PG-APS could stimulate PMN oxidative metabolism either
by opsonization of PG-APS (26) and subsequent binding to
the neutrophil surface or through the formation of C5a, a
soluble complement component which stimulates the PMN
respiratory burst and degranulation (14). To address these
alternativb mechanisms, a homogeneous preparation of PG-
APS (100p60) which can be pelleted out of serum by ultra-
centrifugation (5) was employed. Both the opsonized 100p60
PG-APS fragments as well as the activated (PG-APS-free)
serum lead to PMN stimulation, suggesting that more than
one mechanismn was operative.
The products of PMN oxidativl metabolism (superoxide
anion, hydrogen peroxide, and hydroxyl radicals) are reduc-
tion products which have both mlcrobicidal and cytotoxic
properties (20). Leakage or secretion of these toxic oxygen
reduction products leads to tissue damage and contributes to
the pathogenesis of inflammation (19). Previous studies have
shownl that only a small portioh of the oxygen consumed
during phagocytosis of opsonized particles is recovered as
02 unless the cells are pretreated with cytochalasin B to
inhibit phagosome closure (28). However, in response to
phorbol myristate acetate, a soluble triggering agent, 02 iS
secreted into the extracellular space rather than into phago-
cytic vacuoles (22). Extracellular secretion of oxygen radi-
cals enhances tumor lysis (23) and could potentially promote
tissue damage, either directly or by interfering with antipro-
teases important in control of chronic ihflammation (17).
During recent studies of the microscopic interaction of PG-
APS with human PMNs, PryzWansky et al. (26) noted
neutrophil capping, a morphological configuration most con-
sistent with microtubular disaggregation (24). These results
suggested the possibility of an alternative mode of secretion
of O2 reduction products in response to PG-APS which
might favor tissue inflammation. To examine this possibility,
we studied the stoichiometry of 02 consumption with re-
spect to O2 release by PG-APS-stimulated PMNs. In the
absence of cytochalasin B, the O2 recovered represented
only 20% of the oxygen consumed. When cells were pre-
treated with cytochalasin B, PG-APS-stimulated O2 release
increased to 72% of the 02 consumed. Cytochalasin B
reduced overall 02 consumption to 68% of the untreated PG-
APS-stimulated control. Similar rediuctions in oxygen con-
sumption by cytochalasin B with opsonized particles have
been observed, presumably as a consequence of decreased
stimulus (particle) binding to the cells (6, 27, 28). Our results
demonstrate that most of the O2 formed by PG-APS
stimulation is localized into phagocytic vacuoles, and maxi-
mal recovery of 02 is demonstrated only after phagosome
formation is inhibited, which suggests that PG-APS is han-
dled by the cell in a manner similar to other phagocytic
stimuli.
The observations reported are consistent with the concept
TABLE 2. Effect of opsonized PG-APS on PMN HMS activity'
Stimulus F cpm SD expt
Resting PMNs 501 ±124 7
50 ,ug of nonopsonized PG-APS per ml 870 +613 5
50 ,ug of nonopsonized PG-APS per ml 1,851b ±842 5
+ 10% serum
50 ,ug of opsonized PG-APS per ml 1,842b +654 3
(bound complement)
First wash supernatant (contains soluble 1,295b +180 3
comiplement components)
a Each individual experiment was performed in triplicate. Numbers are the
mean counts per minute and standard deviation of separate experiments.
b P < 0.05 compared with resting PMNs.
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that phagocytic cells may play a role in the pathogenic
mechanisms of PG-APS-induced tissue injury. Page et al.
(25) described the secretion of lysosomal enzymes by mouse
peritoneal macrophages activated by PG-APS and proposed
that this could be a factor in the phlogistic properties of
bacterial cell wall debris. We have shown that PG-APS
interacts with serum and may then stimulate PMNs and
other phagocytes as well. Our results demonstrate that PG-
APS is a less potent stimulus than opsonized zymosan or
phorbol esters and that most O2 formed is localized in
vacuoles which might be expected to protect the surrounding
tissues from injury. On the other hand, PG-APS is only
poorly degraded and may remain accessible for long periods
of time. Furthermore, the minimal concentration of 02
reduction products necessary for tissue inflammation or
inactivation of serum-mediated defenses is not known. Our
results confirm the interaction of PG-APS with the comple-
ment system and suggest that further studies are warranted
to characterize the contribution of phagocytic cells to the
chronic inflammation observed in animals exposed to this
material.
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